Your browser doesn't support javascript.
Early evidence of COVID-19 vaccine effectiveness within the general population of California
Kristin Andrejko; Jake M Pry; Jennifer F Myers; Nicholas P Jewell; John Openshaw; James Watt; Seema Jain; Joseph A Lewnard; - California COVID-19 Case-Control Study Team.
  • Kristin Andrejko; University of California at Berkeley
  • Jake M Pry; California Department of Public Health
  • Jennifer F Myers; California Department of Public Health
  • Nicholas P Jewell; London School of Hygiene and Tropical Medicine
  • John Openshaw; Stanford University
  • James Watt; California Department of Public Health
  • Seema Jain; California Department of Health
  • Joseph A Lewnard; University of California Berkeley
  • - California COVID-19 Case-Control Study Team;
Preprint Dans Anglais | medRxiv | ID: ppmedrxiv-21255135
ABSTRACT
BackgroundEstimates of COVID-19 vaccine effectiveness under real-world conditions, and understanding of barriers to uptake, are necessary to inform vaccine rollout. MethodsWe enrolled cases (testing positive) and controls (testing negative) from among the population whose SARS-CoV-2 molecular diagnostic test results from 24 February-29 April 2021 were reported to the California Department of Public Health. Participants were matched on age, sex, and geographic region. We assessed participants self-reported history of COVID-19 vaccine receipt (BNT162b2 and mRNA-1273). Participants were considered fully vaccinated two weeks after second dose receipt. Among unvaccinated participants, we assessed willingness to receive vaccination, when eligible. We measured vaccine effectiveness (VE) via the matched odds ratio of prior vaccination, comparing cases with controls. ResultsWe enrolled 1023 eligible participants aged [≥]18 years. Among 525 cases, 71 (13.5%) received BNT162b2 or mRNA-1273; 20 (3.8%) were fully vaccinated with either product. Among 498 controls, 185 (37.1%) received BNT162b2 or mRNA-1273; 86 (16.3%) were fully vaccinated with either product. Two weeks after second dose receipt, VE was 86.8% (95% confidence interval 68.6-94.7%) and 85.6% (69.1-93.9%) for BNT162b2 and mRNA-1273, respectively. Fully vaccinated participants receiving either product experienced 91.3% (79.7-96.3%) and 68.3% (28.5-86.0%) VE against symptomatic and asymptomatic infection, respectively. Among unvaccinated participants, 42.4% (159/375) residing in rural regions and 23.8% (67/281) residing in urban regions reported hesitancy to receive COVID-19 vaccination. ConclusionsAuthorized mRNA vaccines are effective at reducing documented SARS-CoV-2 infections within the general population of California. Vaccine hesitancy presents a barrier to reaching coverage levels needed for herd immunity. Brief pointsO_LIVaccination is preventing documented SARS-CoV-2 infection in California, with 68% and 91% effectiveness against asymptomatic and symptomatic infection, respectively. C_LIO_LIVaccine effectiveness was equivalent for BNT126b2 and mRNA-1273. C_LIO_LIOnly 66% of unvaccinated participants were willing to receive the vaccine when eligible. C_LI
Texte intégral: Disponible Collection: Preprints Base de données: medRxiv Type d'étude: Étude observationnelle / Synthèse de preuves Les sujets: Vaccins langue: Anglais Année: 2021 Type de document: Preprint

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Collection: Preprints Base de données: medRxiv Type d'étude: Étude observationnelle / Synthèse de preuves Les sujets: Vaccins langue: Anglais Année: 2021 Type de document: Preprint